论文部分内容阅读
目的评价左西孟旦对老年急性心衰血浆N端B型利钠肽前体(N-proBNP)的影响。方法选择34例确诊为老年急性心衰住院患者,随机分为常规治疗组和左西孟旦组各17例。用药前以及开始用药后2周两组均行NT-proBNP检测,且分别与治疗前诸指标进行比较。结果左西孟旦能显著降低老年急性心衰患者血浆NT-proBNP水平(P<0.05)。结论1、血浆NT-proBNP水平反映心功能受损的敏感指标。2、左西孟旦显著降低老年急性心衰血浆NT-proBNP水平。
Objective To evaluate the effect of levosimendan on plasma N-terminal proBNP (N-proBNP) in elderly patients with acute heart failure. Methods 34 patients diagnosed as elderly patients with acute heart failure were randomly divided into routine treatment group and levosimendan group, 17 cases each. Before treatment and 2 weeks after the start of medication, NT-proBNP was detected in both groups, and compared with the indexes before treatment. Results Levosimendan significantly reduced plasma NT-proBNP levels in elderly patients with acute heart failure (P <0.05). Conclusion 1, NT-proBNP plasma levels reflect sensitive indicators of impaired cardiac function. Levosimendan significantly reduced plasma NT-proBNP levels in elderly patients with acute heart failure.